Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” ...

The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a ...

A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications ...

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help ...

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, ...

The drug, which Invivyd sees as a potential treatment and “targeted alternative” for the vaccine-hesitant, comes as measles ...

On a conference call with analysts, Gilead walked through how a string of recent deals focused on cancer and autoimmune ...

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts ...

Colorado drugmaker Ambrosia Biosciences has landed $100 million to pursue an oral obesity drug it’s hoping can compete with a ...

Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator ...

Shah Capital, which has agitated for change at the vaccine maker for years, is calling on fellow shareholders to end what it ...